Who is sponsoring NCT02206230?

NCT02206230 is sponsored by AHS Cancer Control Alberta.

What drugs are being tested in NCT02206230?

Interventions in NCT02206230: Hypofractionated radiation therapy, Standard radiation therapy.

What condition does NCT02206230 study?

NCT02206230 studies Glioblastoma.

Is NCT02206230 still recruiting?

NCT02206230 is currently completed. Last updated 31 January 2024.

Last reviewed 2024-01-31 · How we verify

NCT02206230

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial of Hypofractionated Radiation Therapy for Glioblastoma

Completed Phase 2 Last updated 31 January 2024

What this trial tests

Phase 2 trial testing Hypofractionated radiation therapy in Glioblastoma in 133 participants. Completed in 14 February 2023.

Timeline

25 September 2014

Primary endpoint
14 February 2023

14 February 2023

Quick facts

Lead sponsor	AHS Cancer Control Alberta
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	133
Start date	25 September 2014
Primary completion	14 February 2023
Estimated completion	14 February 2023
Sites	1 location across Canada

Drugs / interventions tested

Hypofractionated radiation therapy — full drug profile →
Standard radiation therapy

Conditions studied

Glioblastoma — all drugs for Glioblastoma →

Sponsor

AHS Cancer Control Alberta — full company profile →

Who can join

Adults 18 to 70, any sex, with Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is being done to compare standard radiation therapy with hypofractionated radiation therapy for patients with newly diagnosed glioblastoma

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Exploiting Gene Expression Kinetics in Conventional Radiotherapy, Hyperfractionation, and Hypofractionation for Targeted Therapy.
Makinde AY, Eke I, Aryankalayil MJ, Ahmed MM, et al · · 2016 · cited 9× · PMID 27619247 · DOI 10.1016/j.semradonc.2016.07.001
Dosimetric predictors of toxicity in a randomized study of short-course vs conventional radiotherapy for glioblastoma.
Yang F, Dinakaran D, Heikal AA, Yaghoobpour Tari S, et al · · 2022 · cited 7× · PMID 36273738 · DOI 10.1016/j.radonc.2022.10.016
Role of Podoplanin (PDPN) in Advancing the Progression and Metastasis of Glioblastoma Multiforme (GBM).
Sharma B, Agriantonis G, Shafaee Z, Twelker K, et al · · 2024 · cited 4× · PMID 39682237 · DOI 10.3390/cancers16234051

Verify or expand the search:

Other trials of Hypofractionated radiation therapy

Trials testing the same drug.

NCT06325774 — Radical Hypofractionated Radiotherapy for Localized Prostate Cancer · NA · recruiting
NCT06325995 — Hypofractionated Post-prostatectomy Radiotherapy (HYPORT)for Localized Prostate Cancer · NA · recruiting
NCT05775757 — SMC Radiation Oncology Breast Cancer Cohort Study · recruiting
NCT04318717 — Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma · Phase 2 · recruiting
NCT03212235 — Hypofractionated Radiation Therapy for Glioblastoma · Phase 2 · unknown

Other recruiting trials for Glioblastoma

Currently open trials in the same condition.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other AHS Cancer Control Alberta trials

Trials by the same sponsor.

NCT05128734 — Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) · Phase 2 · not yet recruiting
NCT06860542 — Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis · Phase 2 · recruiting
NCT05345847 — Steroid Sparing in Immune Related Hepatitis (irH) · NA · recruiting
NCT05407987 — Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery) · Phase 3 · recruiting
NCT05421416 — Loratadine for the Prevention of G-CSF-related Bone Pain · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02206230 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AHS Cancer Control Alberta
Last refreshed: 31 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02206230.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing